Biotech stock Alkermes plunges 20% after FDA refuses to review its depression treatment

Alkermes announced Monday it received a "Refusal to File" letter from the U.S. Food and Drug Administration regarding the company's application for a new drug called ALKS 5461.
Source: CNBC

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>